Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America.

Genberg BL, Wilson IB, Bangsberg DR, Arnsten J, Goggin K, Remien RH, Simoni J, Gross R, Reynolds N, Rosen M, Liu H; MACH14 Investigators..

AIDS. 2012 Jul 17;26(11):1415-23. doi: 10.1097/QAD.0b013e328354bed6.

2.
3.

Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda.

Haberer JE, Musinguzi N, Boum Y 2nd, Siedner MJ, Mocello AR, Hunt PW, Martin JN, Bangsberg DR.

J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):386-92. doi: 10.1097/QAI.0000000000000737.

4.

Improved adherence to modern antiretroviral therapy among HIV-infected injecting drug users.

Mann B, Milloy MJ, Kerr T, Zhang R, Montaner J, Wood E.

HIV Med. 2012 Nov;13(10):596-601. doi: 10.1111/j.1468-1293.2012.01021.x.

5.

Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels.

Parienti JJ, Das-Douglas M, Massari V, Guzman D, Deeks SG, Verdon R, Bangsberg DR.

PLoS One. 2008 Jul 30;3(7):e2783. doi: 10.1371/journal.pone.0002783.

7.

Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy.

Gandhi M, Ameli N, Bacchetti P, Anastos K, Gange SJ, Minkoff H, Young M, Milam J, Cohen MH, Sharp GB, Huang Y, Greenblatt RM.

Clin Infect Dis. 2011 May;52(10):1267-75. doi: 10.1093/cid/cir131.

8.

Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial.

Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, Jack W, Habyarimana J, Sadatsafavi M, Najafzadeh M, Marra CA, Estambale B, Ngugi E, Ball TB, Thabane L, Gelmon LJ, Kimani J, Ackers M, Plummer FA.

Lancet. 2010 Nov 27;376(9755):1838-45. doi: 10.1016/S0140-6736(10)61997-6.

PMID:
21071074
9.

Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda.

Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, Mugyenyi P, Quinn TC, Bangsberg DR.

AIDS. 2007 May 11;21(8):965-71.

PMID:
17457090
10.

HIV-Infected Ugandan Women on Antiretroviral Therapy Maintain HIV-1 RNA Suppression Across Periconception, Pregnancy, and Postpartum Periods.

Matthews LT, Ribaudo HB, Kaida A, Bennett K, Musinguzi N, Siedner MJ, Kabakyenga J, Hunt PW, Martin JN, Boum Y, Haberer JE, Bangsberg DR.

J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):399-406. doi: 10.1097/QAI.0000000000000874.

PMID:
26495883
11.

A marginal structural model to estimate the causal effect of antidepressant medication treatment on viral suppression among homeless and marginally housed persons with HIV.

Tsai AC, Weiser SD, Petersen ML, Ragland K, Kushel MB, Bangsberg DR.

Arch Gen Psychiatry. 2010 Dec;67(12):1282-90. doi: 10.1001/archgenpsychiatry.2010.160.

12.

Impact of use of alcohol and illicit drugs by AIDS patients on adherence to antiretroviral therapy in Bahia, Brazil.

Teixeira C, Dourado Mde L, Santos MP, Brites C.

AIDS Res Hum Retroviruses. 2013 May;29(5):799-804. doi: 10.1089/AID.2012.0296.

PMID:
23294471
13.

Longitudinal Analysis of Adherence to First-Line Antiretroviral Therapy: Evidence of Treatment Sustainability from an Indian HIV Cohort.

Shet A, Kumarasamy N, Poongulali S, Shastri S, Kumar DS, Rewari BB, Arumugam K, Antony J, De Costa A, D'Souza G.

Curr HIV Res. 2016;14(1):71-9.

PMID:
26303008
14.

Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.

Nieuwkerk PT, Sprangers MA, Burger DM, Hoetelmans RM, Hugen PW, Danner SA, van Der Ende ME, Schneider MM, Schrey G, Meenhorst PL, Sprenger HG, Kauffmann RH, Jambroes M, Chesney MA, de Wolf F, Lange JM; ATHENA Project..

Arch Intern Med. 2001 Sep 10;161(16):1962-8.

PMID:
11525698
15.

Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries.

Hirsch JD, Rosenquist A, Best BM, Miller TA, Gilmer TP.

J Manag Care Pharm. 2009 Jan-Feb;15(1):32-41.

16.

Measuring adherence to antiretroviral therapy in children and adolescents in western Kenya.

Vreeman RC, Nyandiko WM, Liu H, Tu W, Scanlon ML, Slaven JE, Ayaya SO, Inui TS.

J Int AIDS Soc. 2014 Nov 25;17:19227. doi: 10.7448/IAS.17.1.19227.

17.

Time patterns of adherence and long-term virological response to non-nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon.

Meresse M, Carrieri MP, Laurent C, Kouanfack C, Protopopescu C, Blanche J, Cohen J, Laborde-Balen G, Aghokeng AF, Spire B, Moatti JP, Delaporte E, Boyer S; Stratall ANRS 12110/ESTHER Study Group..

Antivir Ther. 2013;18(1):29-37. doi: 10.3851/IMP2535.

PMID:
23358393
18.

Young age predicts poor antiretroviral adherence and viral load suppression among injection drug users.

Hadland SE, Milloy MJ, Kerr T, Zhang R, Guillemi S, Hogg RS, Montaner JS, Wood E.

AIDS Patient Care STDS. 2012 May;26(5):274-80. doi: 10.1089/apc.2011.0196.

19.

The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis.

Al-Dakkak I, Patel S, McCann E, Gadkari A, Prajapati G, Maiese EM.

AIDS Care. 2013;25(4):400-14. doi: 10.1080/09540121.2012.712667. Review.

20.

Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.

Meresse M, March L, Kouanfack C, Bonono RC, Boyer S, Laborde-Balen G, Aghokeng A, Suzan-Monti M, Delaporte E, Spire B, Carrieri MP, Laurent C; Stratall ANRS 12110/ESTHER Study Group..

HIV Med. 2014 Sep;15(8):478-87. doi: 10.1111/hiv.12140.

Items per page

Supplemental Content

Support Center